Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Robotic Retroperitoneal Lymph Node Dissection (R-RPLND) as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma

NCT05345158 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT05345158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05345158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Robotic Retroperitoneal Lymph Node Dissection (R-RPLND) as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Recruiting
Start date
February 23, 2022
Completion date
November 30, 2030
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphadenopathy retroperitoneal, stage ii testicular seminoma